Login to Your Account

Argenx bags $40M up front in $685M immuno-oncology pact with Abbvie

By Cormac Sheridan
Staff Writer

Thursday, April 21, 2016

DUBLIN – Argenx NV is getting $40 million up front plus up to $645 million in milestones in an immuno-oncology pact with Abbvie Inc., based around its first-in-class, preclinical antibody, ARGX-115, which inhibits Garp.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription